Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi

被引:20
|
作者
Gopal, Satish [1 ,2 ,3 ,4 ]
Liomba, N. George [1 ]
Montgomery, Nathan D. [5 ]
Moses, Agnes [1 ,4 ]
Kaimila, Bongani [1 ]
Nyasosela, Richard [6 ]
Chikasema, Maria [1 ]
Dhungel, Bal M. [7 ]
Kampani, Coxcilly [1 ]
Sanders, Marcia K. [8 ]
Krysiak, Robert [1 ]
Dittmer, Dirk P. [2 ,3 ,8 ]
Fedoriw, Yuri [2 ,5 ]
机构
[1] UNC Project Malawi, Lilongwe, Malawi
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Program Global Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Med, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA
[4] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi
[5] Univ N Carolina, Div Hematopathol, Dept Pathol & Lab Med, Chapel Hill, NC USA
[6] Kamuzu Cent Hosp, Lilongwe, Malawi
[7] United Nations Dev Program, Lilongwe, Malawi
[8] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA
关键词
HIV; multicentric Castleman disease; Kaposi sarcoma; Kaposi sarcoma-associated herpesvirus; non-Hodgkin lymphoma; sub-Saharan Africa; HERPESVIRUS; RITUXIMAB; LYMPHOMA; CHEMOTHERAPY; PATHOLOGY; AFRICA;
D O I
10.7448/IAS.18.1.20122
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Clinical reports of multicentric Castleman disease (MCD) from sub-Saharan Africa (SSA) are scarce despite high prevalence of HIV and Kaposi sarcoma-associated herpesvirus (KSHV). Our objective is to describe characteristics and survival for HIV-associated MCD patients in Malawi. To our knowledge, this is the first HIV-associated MCD case series from the region. Methods: We describe HIV-positive patients with MCD in Lilongwe, and compare them to HIV-associated lymph node Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) patients treated at our centre. All patients were enrolled into a prospective longitudinal cohort study at a national teaching hospital and cancer referral centre serving half of Malawi's 16 million people. We included adult patients] 18 years of age with HIV-associated MCD (n = 6), lymph node KS (n = 5) or NHL (n = 31) enrolled between 1 June 2013 and 31 January 2015. Results and discussion: MCD patients had a median age of 42.4 years (range 37.2-51.8). All had diffuse lymphadenopathy and five had hepatosplenomegaly. Concurrent KS was present for one MCD patient, and four had performance status >= 3. MCD patients had lower median haemoglobin (6.4 g/dL, range 3.6-9.3) than KS (11.0 g/dL, range 9.1-12.0, p = 0.011) or NHL (11.2 g/dL, range 4.5-15.1, p = 0.0007). Median serum albumin was also lower for MCD (2.1 g/dL, range 1.7-3.2) than KS (3.7 g/dL, range 3.2-3.9, p = 0.013) or NHL (3.4 g/dL, range 1.8-4.8, p = 0.003). All six MCD patients were on antiretroviral therapy (ART) with median CD4 count 208 cells/mu L (range 108-1146), and all with HIV RNA <400 copies/mL. Most KS and NHL patients were also on ART, although ART duration was longer for MCD (56.4 months, range 18.2-105.3) than KS (14.2 months, range 6.8-21.9, p = 0.039) or NHL (13.8 months, range 0.2-98.8, p = 0.017). Survival was poorer for MCD patients than lymph node KS or NHL. Conclusions: HIV-associated MCD occurs in Malawi, is diagnosed late and is associated with high mortality. Improvements in awareness, diagnostic facilities, treatment and supportive care are needed to address this likely under-recognized public health problem in SSA.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] A prospective description of HIV-associated multicentric Castleman disease in Malawi
    Tomoka, Tamiwe
    Painschab, Matthew S.
    Montgomery, Nathan D.
    Seguin, Ryan
    Mulenga, Maurice
    Kaimila, Bongani
    Kasonkanji, Edwards
    Zuze, Takondwa
    Nyasosela, Richard
    Nyirenda, Ruth
    Chikasema, Maria
    Tewete, Blessings
    Mtangwanika, Asekanadziwa
    Chiyoyola, Sarah
    Chimzimu, Fred
    Kampani, Coxcilly
    Fedoriw, Yuri
    Gopal, Satish
    HAEMATOLOGICA, 2019, 104 (05) : E215 - E217
  • [2] HIV-associated multicentric Castleman disease
    Reddy, Deepa
    Mitsuyasu, Ronald
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (05) : 475 - 481
  • [3] HIV-associated multicentric Castleman disease
    Oksenhendler, Eric
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (01) : 16 - 21
  • [4] HIV-associated multicentric Castleman's disease
    Stebbing, Justin
    Pantanowitz, Liron
    Dayyani, Farshid
    Sullivan, Ryan J.
    Bower, Mark
    Dezube, Bruce J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (06) : 498 - 503
  • [5] HIV-associated multicentric Castleman's disease
    Naime, Fauzia de Fatima
    Fakhouri, Felipe
    Martins, Carlos Saraiva
    Couto, Wilson Jose
    RARE TUMORS, 2012, 4 (03) : 127 - 129
  • [6] Failure of cidofovir in HIV-associated multicentric Castleman disease
    Berezne, A
    Agbalika, F
    Oksenhendler, E
    BLOOD, 2004, 103 (11) : 4368 - 4369
  • [7] How I treat HIV-associated multicentric Castleman disease
    Bower, Mark
    BLOOD, 2010, 116 (22) : 4415 - 4421
  • [8] A case of HIV-associated multicentric Castleman disease with pulmonary involvement
    Lemay, Anne-Sophie
    Lachapelle, Philippe
    Lemieux, Bernard
    Poirier, Claude
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [9] Brief communication: Rituximab in HIV-associated multicentric Castleman disease
    Bower, Mark
    Powles, Tom
    Williams, Sarah
    Davis, Tom Newsom
    Atkins, Mark
    Montoto, Silvia
    Orkin, Chloe
    Webb, Andy
    Fisher, Martin
    Nelson, Mark
    Gazzard, Brian
    Stebbing, Justin
    Kelleher, Peter
    ANNALS OF INTERNAL MEDICINE, 2007, 147 (12) : 836 - 839
  • [10] Treatment of HIV-associated multicentric Castleman's disease with oral etoposide
    Scott, D
    Cabral, L
    Harrington, WJ
    AMERICAN JOURNAL OF HEMATOLOGY, 2001, 66 (02) : 148 - 150